Perrigo Company (PRGO) announced it has received final approval for the generic version of Sanctura XR. Perrigo had previously prevailed in litigation at both the district and appellate levels. The company said the product has begun shipping immediately.
Sanctura XR is a once-daily medication for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency.
In a separate announcement, Perrigo reported that it has filed an Abbreviated New Drug Application with the U.S. FDA for testosterone topical solution, the generic version of Axiron Topical Solution. Perrigo previously notified Eli Lilly, the owner of the New Drug Application and Acrux DDS PTY Ltd., owners of patents listed in FDA's Orange Book and Lilly and Acrux filed suit on May 24.
For comments and feedback: editorial@rttnews.com